ADMA Biologics, Inc. Annual report pursuant to Section 13 and 15(d)

11. SEGMENTS (Tables)

12 Months Ended

Dec. 31, 2015

Year Ended December 31,	Plasma Collection			Research and
2015	Centers			Development			Corporate			Consolidated

Revenues	$	7,050,283		$	-		$	127,350		$	7,177,633

Cost of product revenue		4,311,461			-			-			4,311,461

Gross profit		2,738,822			-			127,350			2,866,172

Loss from operations		(1,879,243	)		(7,015,946	)		(6,618,618	)		(15,513,807	)

Other expense		-			-			(2,456,123	)		(2,456,123	)

Loss before income taxes		(1,879,243	)		(7,015,946	)		(9,074,741	)		(17,969,930	)

Total assets		2,719,641			-			20,994,876			23,714,517

Depreciation and amortization expense		419,301			-			50,520			469,821

Year Ended December 31,	Plasma Collection			Research and
2014	Centers			Development			Corporate			Consolidated

Revenues	$	5,839,989		$	-		$	75,556		$	5,915,545

Cost of product revenue		3,742,367			-			-			3,742,367

Gross profit		2,097,622			-			75,556			2,173,178

Loss from operations		(1,753,206	)		(9,517,014	)		(4,748,313	)		(16,018,533	)

Other income (expense)		262			-			(1,346,616	)		(1,346,354	)

Loss before income taxes		(1,752,944	)		(9,517,014	)		(6,094,929	)		(17,364,887	)

Total assets		3,073,179			-			23,950,337			27,023,516

Depreciation and amortization expense		198,244			2,729			46,879			247,852